Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States.
The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors.
NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio.
It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells.
The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015.
NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 21 | -0.30 Decreased by -87.50% | -0.18 Decreased by -66.67% |
| Nov 9, 20 | -0.20 Decreased by -25.00% | -0.18 Decreased by -11.11% |
| Aug 7, 20 | -0.20 Decreased by -17.65% | -0.19 Decreased by -5.26% |
| May 11, 20 | -0.19 Increased by +13.64% | -0.17 Decreased by -11.76% |
| Mar 25, 20 | -0.16 Increased by +27.27% | -0.20 Increased by +20.00% |
| Nov 5, 19 | -0.16 Increased by +46.67% | -0.18 Increased by +12.04% |
| Aug 6, 19 | -0.17 Increased by +51.43% | -0.23 Increased by +26.53% |
| May 8, 19 | -0.22 Increased by +37.14% | -0.23 Increased by +6.34% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 21 | 66.00 K Decreased by -2.94% | -87.63 M Decreased by -402.31 K% | Decreased by -132.77 K% Decreased by -414.51 K% |
| Jun 30, 21 | 339.00 K Increased by +33.80 K% | -88.29 M Decreased by -339.42% | Decreased by -26.04 K% Increased by +98.70% |
| Mar 31, 21 | 111.00 K Increased by +428.57% | -92.38 M Decreased by -402.55% | Decreased by -83.23 K% Increased by +4.92% |
| Dec 31, 20 | 111.00 K Increased by +1.13 K% | -92.38 M Decreased by -490.65% | Decreased by -83.23 K% Increased by +52.11% |
| Sep 30, 20 | 68.00 K Increased by +466.67% | -21.78 K Increased by +99.86% | Decreased by -32.02% Increased by +99.98% |
| Jun 30, 20 | 1.00 K Decreased by -94.12% | -20.09 M Decreased by -20.44% | Decreased by -2.01 M% Decreased by -1.95 K% |
| Mar 31, 20 | 21.00 K Increased by +320.00% | -18.38 M Decreased by -2.78% | Decreased by -87.54 K% Increased by +75.53% |
| Dec 31, 19 | 9.00 K Increased by +28.57% | -15.64 M Increased by +9.80% | Decreased by -173.79 K% Increased by +29.84% |